Type 1 long-interspersed nuclear elements (L1s) are autonomous retrotransposable elements that retain the potential for activity in the human genome but are suppressed by host factors. Retrotransposition of L1s into chromosomal DNA can lead to genomic instability, whereas reverse transcription of L1 in the cytosol has the potential to activate innate immune sensors. We hypothesized that HIV-1 infection would compromise cellular control of L1 elements, resulting in the induction of retrotransposition events. Here, we show that HIV-1 infection enhances L1 retrotransposition in Jurkat cells in a Vif-and Vpr-dependent manner.
Type 1 long-interspersed nuclear elements (L1s) are autonomous retrotransposable elements that retain the potential for activity in the human genome but are suppressed by host factors. Retrotransposition of L1s into chromosomal DNA can lead to genomic instability, whereas reverse transcription of L1 in the cytosol has the potential to activate innate immune sensors. We hypothesized that HIV-1 infection would compromise cellular control of L1 elements, resulting in the induction of retrotransposition events. Here, we show that HIV-1 infection enhances L1 retrotransposition in Jurkat cells in a Vif-and Vpr-dependent manner.
In primary CD4
؉ cells, HIV-1 infection results in the accumulation of L1 DNA, at least the majority of which is extrachromosomal. These data expose an unrecognized interaction between HIV-1 and endogenous retrotransposable elements, which may have implications for the innate immune response to HIV-1 infection, as well as for HIV-1-induced genomic instability and cytopathicity. L 1 element DNA sequences comprise approximately 17% of the human genome (1, 2) . Although the bulk of these sequences are in the form of short 5= truncated insertions, an estimated 100 full-length intact elements are present (3, 4) . These intact L1 elements represent the only retrotransposons encoded by the human genome known to be capable of autonomous replication (4-7). Full-length L1 elements are ϳ6 kb in length, comprising a 5=-untranslated region (5=UTR) two open reading frames (ORF1 and ORF2) and a 3=UTR ending in a poly(A) tail (8) . ORF1 encodes a 40-kDa protein with RNA chaperone activity, while ORF2 encodes a 150-kDa protein which possesses the reverse transcriptase (RT) and endonuclease functions required for retrotransposition (6, (9) (10) (11) (12) (13) (14) (15) (16) (17) . Productive retrotransposition is thought to occur by a mechanism termed target-primed reverse transcription (TPRT), where reverse transcription is primed against genomic DNA at the insertion site and thus occurs in concert with integration (18) (19) (20) .
Several cases of genetic disease have been traced to gene disruptions caused by L1 retrotransposition events in germ line cells, and L1 retrotransposition in somatic cells has been implicated in oncogenesis and cancer progression (21) (22) (23) (24) (25) (26) . L1 retrotransposition may also play a role in normal physiology. Previous studies have demonstrated the ability for tagged, engineered L1 elements to retrotranspose in neural progenitor cells, and this, supported by quantitative PCR (qPCR) data showing elevated copy numbers of L1 elements in the adult human brain, has led to the suggestion that L1 retrotransposition may play a role in the generation of neuronal somatic mosaicism (27, 28) . The vast amount of L1 element sequence fixed in the human genome has, however, presented a technical challenge to the isolation of novel endogenous L1 genomic insertions in somatic cells.
Although TPRT appears to be the primary mechanism by which novel genomic L1 insertions are generated, there is considerable evidence that cytosolic reverse transcription of L1, without integration, also occurs. Mice deficient for the DNA exonuclease TREX1 develop inflammatory myocarditis, leading to cardiomyopathy and circulatory failure (29) . This inflammation is caused by the accumulation of cytosolic DNA abundantly represented by L1 and Alu single-stranded DNA (ssDNA), which triggers an IRF3-dependent innate immune response (30) (31) (32) . Supporting reverse transcription as the mode of origin of these L1 and Alu ssDNAs, it has recently been demonstrated that treating TREX1-deficient mice with nucleoside analogue reverse transcriptase inhibitors, previously shown to suppress L1 retrotransposition (33) , ameliorates myocarditis (34) . In humans, loss-of-function mutations in the gene encoding TREX1 cause Aicardi-Goutieres syndrome (AGS), a severe neurological disease, which mimics congenital viral infection (35) . Analogous to the scenario observed in TREX1-deficient mice, cells derived from AGS patients were shown to accumulate ssDNA, which was almost exclusively localized to the cytosol (31) . These data support that a mechanism exists for the reverse transcription of L1 and Alu DNA in the cytosol of cells and indicate that the generation of such reverse transcripts has the potential to trigger innate immune sensors.
Mammalian cells have evolved defense mechanisms responsible for restricting L1 reverse transcription and retrotransposition. These include the suppression of transcription by methylation of CpG islands in the 5= long terminal repeat (LTR) of L1 elements (25, 36, 37) , degradation of transcripts by siRNA mechanisms (38) , and the suppression of retrotransposition by members of the APOBEC3 family of proteins (39) (40) (41) (42) (43) . The APOBEC3 family comprises a cluster of seven genes in primates, expanded relative to the single gene found in rodents (44) . Members of the APOBEC3 family of proteins, in particular APOBEC3G, have been well characterized as restriction factors which prevent the replication of Vif-deficient HIV-1 in primary cells and certain cell lines (45) . This is achieved by editing of cytosines to uracils in the minus strand of the nascent cDNA during reverse transcription (46) (47) (48) . The HIV-1 Vif protein acts as a viral countermeasure which targets a sensitive subset of APOBEC3 proteins for proteasomal degradation (47, (49) (50) (51) (52) (53) (54) . A role for APOBEC3 proteins in defense against retrotransposable elements was first suggested based on the observation that APOBEC3G and other members of the APOBEC3 family have been under strong and constant positive selection pressure throughout the history of primate evolution. Since this history of selection apparently predates the emergence of primate lentiviruses, and the constant rate of selection is inconsistent with the episodic selective pressure that would be applied by an infectious extracellular pathogen, these findings imply that APOBEC3 genes are in conflict with a constant and ancient threat to genomic stability, such as that posed by L1 or other endogenous retrotransposable elements (55) . The data from a number of studies support that the overexpression of APOBEC3 proteins in cell lines suppress the retrotransposition of engineered L1 elements (41, 42, (56) (57) (58) (59) (60) . Different APOBEC3 members exert different levels of suppression with APOBEC3A, -3B, and -3F consistently exhibiting potent effects, whereas APOBEC3G exhibited modest or no activity in the majority of these studies. The suppression of L1 retrotransposition by APOBEC3 proteins were found to be independent of cytosine deamination. Recently, it has been demonstrated that shRNA knockdown of APOBEC3B, but not other APOBEC3 family members, resulted in elevated levels of retrotransposition in human embryonic stem cells (39) . Thus, although additional studies on the role of endogenous APOBEC3 family members in primary cells are required, the overwhelming evidence supports a central role for APOBEC3 proteins in the suppression of L1 retrotransposition.
Given that HIV-1, through the actions of Vif, degrades a number of APOBEC3 proteins including APOBE3C, -3DE, -3F, -3G, and -3H, we reasoned that infection may disrupt natural control of L1 elements, resulting in the induction of reverse transcription and/or retrotransposition. While we highlight the Vif/APOBEC3 axis as a well-characterized interaction by which HIV-1 could interact with L1 elements, we posit that this may represent only one example of potentially diverse defense mechanisms which may cross-react against both exogenous retroviruses, such as HIV-1, and endogenous retrotransposable elements. Hence, the aim of the current study was to determine whether HIV-1 infection, in a general sense, resulted in a measurable impact on L1 retrotransposition.
MATERIALS AND METHODS
Ethics statement. This study was approved by the University of Toronto Institutional Review Board and the University of California at San Francisco (UCSF) Committee on Human Research, and subjects gave written informed consent.
Subjects. Chronic progressors were defined as individuals infected with HIV-1 for Ͼ1 year with a CD4 ϩ T cell count decline of Ͼ50 cells/ mm 3 /year. Viral controllers were defined as individuals infected with HIV-1 for Ͼ1 year, no evidence of a CD4 ϩ T cell count decline, and a viral load of Ͻ5,000 copies of branched DNA/ml.
Primer selection. Primer sequences are given in Table 1 . The number of base mismatches between primers and the consensus sequences of different Alu families are given in Table 2 . None of these mismatches occur at the 3= base of the primer. Three pairs of primers for SYBR qPCR and one set of primers and probe for TaqMan qPCR were designed to quantify the L1 elements. LH2for-LH3rev and LH1for-LH2rev were designed against the 3=UTR of a L1PA2 consensus sequence and incorporate degenerate bases to broaden their range of target elements. LH2for-LH3rev targets the very 3= end of the 3=UTR, while LH1-LH2rev targets a site immediately 5= of this sequence. L1-ORF1 primers and L1-ORF2 primer-probe combinations were designed against conserved sequence regions within an alignment of the six L1 elements responsible for the majority of retrotransposition in the human population (3) .
qPCR of L1 and Alu. DNA was isolated using the Gentra Puregene genomic DNA isolation kit (Qiagen). Real-time PCRs were performed Alu-rev  CGGGTTCAAGCGATTCTCC  L1-ORF1-for  CTCGGCAGAAACCCTACAAG  L1-ORF1-rev  CCATGTTTAGCGCTTCCTTC  L1-3=UTR-LH1-for  AAAGACACATGCACWCRTATGTT  L1-3=UTR-LH2-rev  TTTCTCA(T/C copies). Human gene quantitations were performed using 7 ng of sample gDNA, while L1/Alu were quantified using either 7 ng or 14 pg of gDNA (see Fig. 2 and 3) . A total of 100 ng of DNA was used in each of the enhanced green fluorescent protein (eGFP) and TBP absolute quantitation reactions depicted in Fig. 2C . The reaction conditions for all experiments were as follows: 95°C for 3 min, followed by 36 cycles of 95°C for 15 s and 60°C for 45 s. For SYBR qPCR experiments, the final dissociation stages were run to generate melting curves, and all amplification products gave single peaks. Real-time PCR was monitored and analyzed with a sequence detection system (version 2.0; Applied Biosystems).
Quantitative RT-PCR of APOBEC3. DNase-treated RNA was transcribed into cDNA using random primers and a SuperScript VILO cDNA synthesis kit (Invitrogen) according to manufacturer's instructions. cDNA was diluted, and real-time PCR was performed using Maxima SYBR green qPCR master mix (Fermentas) on a StepOnePlus device (Applied Biosystems). The cycling program was used as follows: 95°C for 15 min, followed by 40 cycles of 94°C for 15 s, 58°C for 30 s, and 72°C for 30 s, followed by a melting-curve program. ␤-Actin primers (Eurogentec) were used as controls according to the manufacturer's instructions. The primers used have been previously reported and are given in Table 1 (61) . Raw threshold cycle (C T ) numbers of amplified gene products were normalized to ␤-actin to account for input cDNA. The relative expression was determined by using the C T method.
Quantitative RT-PCR of L1. RNA was isolated using TRIzol (Invitrogen) and treated with DNase (DNA-free; Ambion) according to the manufacturer's instructions. Reverse transcription was performed using Superscript III (Invitrogen) RT with oligo(dT) 20 and random hexamers. Parallel reactions lacking the RT enzyme were performed. SYBR qPCR was performed as described above with 100 ng of total RNA per reaction.
Preparation of plasmid standards. DNA was prepared from peripheral blood mononuclear cells (PBMC) according to standard methods. PCR was performed in 1ϫ PCR buffer (Invitrogen), 3 mM MgCl 2 , 0.2 mM deoxynucleoside triphosphate (Applied Biosystems), and 1 nM concentrations of each forward and reverse primer. The cycle conditions were as follows: 95°C for 3 min, followed by 36 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s. The products were cloned into pCR2.1 (Invitrogen), linearized by digestion with NcoI, purified by agarose gel electrophoresis, and gel extracted using the Geneclean kit (Qbiogene). Inserts were confirmed by sequencing. For L1 absolute quantitation, linearized 99gfpLRE3 plasmid was used as a standard.
Generation of HIV-1 viruses. The plasmids p197-1 and pNL4-3 were obtained from the NIH AIDS reagent program. Plasmid pNL4-3 encodes full-length infectious HIV-1-NL4-3 virus, whereas p197-1 encodes the 5= portion of NL4-3 and a deletion in vif (62) . A Vif deletion virus was generated by digesting pNL4-3 with AgeI and EcoRI and replacing the excised fragment with that derived from digesting p197-1 with the same enzymes. ⌬Vpu, ⌬Vpr, and ⌬Vif⌬Vpr plasmids were similarly produced using p210-13, p210-19, and p210-25, respectively. Plasmids were transfected into 293T cells using Fugene 6 (Roche). Virus-containing supernatants were collected 4 days posttransfection, and the p24 concentrations were determined by an enzyme-linked immunosorbent assay (ELISA; Zeptometrix). HIV-1 BaL was obtained from the NIH AIDS reagent program and expanded on activated primary CD4 ϩ T cells. Generation of lentiviral vectors. The vif gene from the clade A primary isolate HIV-1 virus ELI was codon optimized for mammalian expression (GenBank accession no. 1325131), synthesized by GenScript and cloned into pUC57 flanked by EcoRI and BamHI restriction sites. This vif gene was cloned into the Lenti-X lentiviral expression system vector (Clontech) by EcoRI/BamHI digestion and ligation. The resultant plasmid or an empty vector control was cotransfected with the Lenti-X HT packaging mix into 293T cells using Lentiphos HT (Clontech). Supernatants were collected at 2 days posttransfection, and the p24 concentrations were determined by ELISA (Zeptometrix).
Primary CD4 ؉ T cell infection. Buffy coats were obtained from Blood Centers of the Pacific (San Francisco, CA) and leukopheresis material was obtained from the University of Toronto. PBMC were purified on a Ficoll gradient and enriched for CD4 ϩ T cells using an Easysep negative selection kit (Stemcell). Cells were cultured in RPMI media supplemented with 15% fetal bovine serum (FBS; Wisent) and 50 U of interleukin-2 (IL-2; Hofmann La Roche)-R15-50/ml at 37°C in 5% CO 2 . Purified CD4 ϩ T cells were stimulated for 48 h prior to infection with 1 g of antibodies to CD3 (clone OKT3; eBioscience) and CD28 (clone CD28.2; eBioscience)/ ml. Cells were infected with HIV-1 at a multiplicity of infection (MOI) of 0.02 to 0.05 over a period of 4 h, followed by a wash step. Intracellular HIV-1-Gag and viability stainings were performed at each time point to determine infection rates and viability.
Flow cytometry. CD4 ϩ and viability stainings were performed prior to cell permeabilization using anti-CD4-PerCP, anti-CD4-APC (SK3 clone; BD), and/or amine-red (Molecular Probes). Cells were permeabilized using Cytofix/Cytoperm, and subsequent stainings were performed in Perm/Wash buffer (BD). HIV-1-Gag stainings were performed using either fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated Kc57 anti-Gag antibody (Beckman Coulter). APOBEC3G expression analyses were performed using either rabbit anti-hAPOBEC3G polyclonal antibody (Immunodiagnostics) or rabbit IgG isotype control antibody (Abcam) at concentrations of 5 g/ml, followed by a secondary fluorochrome (PE)-conjugated donkey anti-rabbit antibody (eBioscience). Sorting experiments were performed on a FACSVantage DiVA cell sorter (BD), and nonsorting experiments were performed on a FACSCalibur instrument (BD). Analysis was performed using FlowJo software (TreeStar).
Purification of HMW genomic DNA. A total of 5 g of total DNA was separated on a 0.8% agarose gel. High-molecular-weight (HMW) DNA bands were excised and purified using a Puregene gel extraction kit (Sigma).
Retrotransposition assay. The in vitro L1 retrotransposition assay is a modified version of a method which has been described elsewhere (6, 7, 63) . Jurkat cells were maintained in RPMI 1640-15% FBS. These cells were transfected with a plasmid containing a puromycin resistance gene and either the retrotransposition-competent human L1 element LRE3 (99gfpLRE3) or an L1 element that had been rendered retrotransposition incompetent by the introduction of point mutations in ORF1 (99gfpJM111) using 8 l of DMRIE-C reagent (Invitrogen). Selection with 1 g of puromycin/ml was initiated at 48 h posttransfection and continued for 28 days. Amounts of virus ranging from 10 to 250 ng of p24 of NL4-3 or 200 ng of p24 of NL4-3⌬Vif, NL4-3⌬Vpu, NL4-3⌬Vpr, or NL4-3⌬Vif⌬Vpr were purified through a 20% sucrose cushion by centrifugation at 16,813 ϫ g for 1 h prior to use in infections. Infections of 5 ϫ 10 5 Jurkat cells were performed for each virus, without a subsequent wash step, and aliquots were taken at the indicated time points. eGFP expression and intracellular HIV-1-Gag expression were analyzed by flow cytometry as described above.
Targeted genomic difference analysis. Template DNA was isolated from CD4 ϩ T cells 168 h postinfection with HIV-1-NL4-3, as well as from mock-infected controls. Preparation of tracer and driver DNA: digestion of genomic DNAs, adapter ligation, and PCR amplification of L1-flanking regions were performed as described previously (64) . We amplified 1-ng aliquots of DNA according to a step-out PCR procedure with set A (0.01 M A1A2, 0.2 M A2, and 0.2 M L2) or set B (0.01 M A2L2, 0.2 M A2, and 0.2 M A1) primers for 15 cycles of the following: 95°C for 15 s, 57°C for 10 s, and 72°C for 90 s. We digested 150 ng each of the resulting tracer A and B samples, and 3,000 ng of the mock amplicon (driver) with Exo III nuclease separately at 16°C using the following conditions: tracer A, 20 U of Exo III, 11 min (40 terminal nucleotides to be removed); tracer B, 20 U, 14 min (60 nucleotides to be removed); and driver, 400 U, 11 min (40 residues to be removed). We mixed 15 ng of each of the digested tracer A and B samples with 1,500 ng of digested driver. DNA samples were purified by phenol-chloroform extraction, precipitated with ethanol, and dissolved in 3 l of hybridization buffer (0.5 M NaCl, 50 mM HEPES [pH 8.3],0.2 mM EDTA). The suppression adapter sequences were as follows: set 1 included A1A2 (adapter oligonucleotide, 44 nucleotides [nt] in length; 5=-CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCG GGCAGGT-3=), A3 (oligonucleotide complementary to the adapter 3=-terminal part, 10 nt; 5=-GGCCCGTCCA-3=), A1 ("outer" PCR primer, 22 nt; 5=-CTAATACGACTCACTATAGGGC-3=), and A2 ("inner" primer for nested PCR, 22 nt; 5=-TCGAGCGGCCGCCCGGGCAGGT-3=), and set 2 included B1B2 (adapter oligonucleotide, 43 nt; 5=-TGTAGCGTGA AGACGACAGAAAGGGCGTGGTGCGGAGGGCGGT-3=), B3 (oligonucleotide complementary to the adapter 3=-terminal part, 11 nt; 5=-GC CTCCCGCCA-3=), and B1 ("outer" PCR primer, 21 nt; 5=-TGTAGCGT GAAGACGACAGAA-3=).
RESULTS

HIV-1 infection results in enhanced levels of L1 retrotransposition in Jurkat cells.
We tested the effect of HIV-1 infection of L1 retrotransposition using an in vitro eGFP-based assay, a modified version of a method that has been previously described (see Fig.  2A ) (6, 7, 63) . Previously, this assay has been carried out in either 293T or HeLa cells, both of which can be transfected at high efficiency by the Ͼ18-kb L1 retrotransposition assay plasmid. However, both of these transformed cell lines are permissive to replication by Vif-deleted HIV-1 (when transfected with the required receptors and coreceptors), indicating that at least some of the restriction factors relevant to the present study, including APOBEC3G, are not expressed. We felt it critical that these experiments be performed in cells that were not permissive, or at least only semipermissive, to HIV-1-⌬Vif. We encountered a technical challenge whereby HIV-1-⌬Vif nonpermissive cell lines (with intact APOBEC3 systems) were consistently resistant to transfection with DNA plasmids. Recently, it has been demonstrated that APOBEC3 proteins mediate the clearance of foreign DNA from cells, likely underlying this observation (65) . We were able to find a compromise in Jurkat cells, which have been described as semipermissive to HIV-1-⌬Vif and which we were able to transfect with DNA plasmids, albeit at low efficiencies. Since Jurkat cells lines can be quite divergent, we first confirmed the semipermissiveness of our cell line. We observed that, whereas NL4-3⌬Vif failed to replicate in the nonpermissive H9 cell line, an input of 10 ng of HIV-1 did result in detectable replication on Jurkat cells, although this was impaired relative to a parallel infection with wild-type NL4-3 ( Fig. 1A and B) . Next, we measured levels of mRNA for APOBEC3A through -3H by qPCR and found that our Jurkat cells expressed all seven of these family members with APOBEC3C, -3D, and -3A in the greatest abundance (Fig. 1C) . Thus, the Jurkat cells used in the current study are semipermissive to HIV-1 infection and do express the Vif-sensitive APOBEC3 family members C, D, F, G, and H addition to other family members.
Jurkat cells were transfected with a plasmid containing the retrotransposition-competent human L1 element LRE3 (99gfpLRE3) or an L1 element that had been rendered retrotransposition incompetent by the introduction of point mutations in ORF1 (99gfpJM111). The LRE3 L1 element was cloned from a patient with a case of chronic granulomatous disease that was caused by the retrotransposition of this element into the X-linked gene CYBB (66) . The 3=UTR of the L1 element in these plasmids contains an eGFP cassette in inverse orientation, interrupted by an intron in the same transcriptional orientation as L1. Expression of eGFP occurs only when the element has been transcribed, spliced, reverse transcribed, and integrated into the genome (retrotransposed). Since Jurkat cells were only transfectable with these Ͼ18-kb plasmids at fairly low efficiencies, cells were selected with puromycin for 28 days prior to initiating assays. At this point, we typically observed eGFP expression in 2 to 8% of 99gfpLRE3-transfected Jurkat cells, and an absence of eGFP expression in the 99gfpJM111 controls. These cells were then infected with HIV-1-NL4-3 or maintained as a mock-infection control and analyzed for eGFP and HIV-1-Gag expression by flow cytometry. Within infection cultures, we considered bystander cells (Gag Ϫ ) separately from infected cells (Gag ϩ ). We consistently observed that the percentage of eGFP ϩ cells increased progressively in Gag ϩ HIV-1-NL4-3-infected cells, peaking at 4 days postinfection (Fig. 2B ). To confirm that the increased level of eGFP observed in HIV-1-infected cells was indicative of an increased level of L1 retrotransposition, we performed TaqMan absolute qPCR of spliced eGFP and standardized this to the single-copy gene TBP (41) . We observed 5 to 8 copies of spliced eGFP DNA (representing L1 integration events) per cell at baseline in cells that had been stably transfected with 99gfpLRE3 for 28 days. This was in contrast to a lack of spliced eGFP in cells that had been stably transfected with the retrotransposition-incompetent 99gfpJM111 control (Fig.  2C) . Levels of spliced eGFP in 99gfpLRE3-transfected cells increased progressively to a peak of 27 Ϯ 5.7 copies/cell by day 6 postinfection, concomitant with the peak of HIV-1 infection, and then began to decline. This closely paralleled the percentage of eGFP ϩ cells (%eGFP ϩ ), as measured by flow cytometry which peaked at 6.3% Ϯ 0.2% at day 6 postinfection (Fig. 2C) . These data support that the observed increase in eGFP expression frequencies in HIV-1-infected 99gfpLRE3-transfected cells are representative of the accumulation L1 retrotransposition events. The frequencies of eGFP expression as measured by flow cytometry do, however, underestimate true retrotransposition frequency, likely for reasons which have previously been suggested by others: (i) L1 element insertions are frequently 5= truncated, and any retrotransposition events that do not deliver the full eGFP cassette would not be scored; (ii) eGFP insertions into genomic sites which do not favor transcription may be silent; (iii) eGFP expression can be lost by mutation of the coding sequence, or by methylation of the insertion site; and (iv) since eGFP may be toxic when expressed at high levels, positive cells may be preferentially lost over the course of the assay (7, 67) . Thus, HIV-1 results in the induction of L1 retrotransposition within infected Jurkat cells.
HIV-1-Vif is necessary for maximal induction of L1 retrotransposition. In order to determine whether HIV-1-Vif plays a role in the induction of L1 retrotransposition, we compared the effects of infection with wild type (wt) and Vif deletion (⌬Vif) HIV-1-NL4-3 on eGFP-expression frequencies. Using a previously validated intracellular staining flow cytometric assay (68), we were able to readily detect APOBEC3G protein expression in uninfected Jurkat cells (Fig. 2D) . This is consistent with our observations of impaired replication of HIV-1-NL4-3⌬Vif in these cells compared to wt HIV-1-NL4-3, indicating that these Jurkat cells are only semipermissive to HIV-1-⌬Vif replication (Fig. 1) . Thus, the APOBEC3 system is at least partially intact in these cells and is vulnerable to impairment by Vif. Confirming this, infection of Jurkat cells with wt HIV-1-NL4-3, but not with HIV-1-NL4-3⌬Vif, resulted in a reduction in APOBEC3G levels (Fig. 2D) . High titers of both HIV-1-NL4-3 and HIV-1-NL4-3⌬Vif were used in this and in subsequent experiments in order to obtain high levels of short-term infection despite the replicative deficiency of the ⌬Vif virus. Summary retrotransposition data from day 4 postinfection are shown in Fig. 2E , with 36% Ϯ 1.2% of Gag ϩ cells expressing eGFP in the HIV-1-NL4-3 infections compared to 14% Ϯ 0.5% of Gag Ϫ cells in the same sample. Substantially lower frequencies of eGFP ϩ cells were observed in HIV-1-NL4-3⌬Vif infection cultures with 18% Ϯ 0.5% of Gag ϩ cells expressing eGFP versus 10% Ϯ 0.3% of Gag Ϫ cells (Fig. 2E , P Ͻ 0.0001 for differences between any two of the groups depicted). In a separate experiment, we infected Jurkat cells with twice the amount of ⌬Vif virus as wt virus (determined by p24 concentration), resulting in a higher level of infection with the former virus. Within the Gag ϩ population we continued to observe a markedly greater frequency of eGFP ϩ cells in wt infections compared to ⌬Vif infections (Fig.  2F) . Thus, HIV-1-induced L1 retrotransposition was predominantly limited to productively infected cells, with a substantially lesser bystander effect, and was largely dependent upon the presence of HIV-1-Vif protein.
HIV-1-Vif is sufficient to enhance L1 retrotransposition frequencies. To determine whether the expression of Vif was sufficient for the induction of L1 retrotransposition, we used replication defective lentiviral vectors to transduce stably 99gfpLRE3-transfected Jurkat cells with a codon-optimized version of HIV-1-vif. Transduction of these cells with HIV-1-vif consistently resulted in a significant decrease in APOBEC3G levels in comparison to cells infected with an empty lentiviral vector control (Fig.  2G ). This decrease in APOBEC3G was observed at 1 and 2 days postransduction and then began to normalize by day 3, presumably reflecting selective outgrowth of nontransduced cells. We consistently observed strikingly elevated levels of eGFP, resultant from L1 retrotransposition events, in cells transduced with HIV-1-vif compared to empty vector controls (11% Ϯ 0.6% versus 17% Ϯ 0.8%, P ϭ 0.0002). Therefore, expression of the Vif protein is sufficient for the induction of L1 retrotransposition events in Jurkat cells.
HIV-1-Vpr is necessary for maximal induction of L1 retrotransposition. Next, we determined whether the other HIV-1 accessory proteins Vpr and Vpu play a role in the induction of L1 retrotransposition. 99gfpLRE3-transduced Jurkat cells were infected with either wt HIV-1-NL4-3, HIV-1-NL4-3⌬Vpu, HIV-1-NL4-3⌬Vif, HIV-1-NL4-3⌬Vpr, HIV-1-NL4-3⌬Vif⌬Vpr or maintained as mock-infected controls. We tuned our input levels of each of these viruses over several iterations of this experiment such that in all cultures (except for mock) we observed Ͼ40% Gag ϩ cells on day 4 postinfection. The levels of retrotransposition were measured within the Gag ϩ subsets for infected samples (all cells were considered for mock). We did not observe a significant difference in frequencies of retrotransposition between the wt HIV-1-NL4-3 and HIV-1-NL4-3⌬Vpu infections. As in previous experiments, we observed that HIV-1-NL4-3⌬Vif induced a lower level of retrotransposition than wt virus but that this was still higher than the frequency observed in the mock condition ( Fig. 2I ). The ⌬Vpr virus was observed to result in an even lesser frequency of retrotransposition than ⌬Vif virus, and the frequency in the ⌬Vif⌬Vpr infection was not significantly different from the mock control. These data indicate that Vif and Vpr independently contribute to the induction of L1 retrotransposition in HIV-1-infected cells.
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HIV-1 drives the accumulation of L1 DNA in infected primary CD4
؉ T cells. The outcome of a L1 retrotransposition event is the generation of a novel copy of the element (often 5= truncated) in the genome. Thus, to begin to study the effect of HIV-1 infection on L1 retrotransposition in primary CD4
ϩ T cells, we quantified L1 DNA from cells that had either been infected in vitro for 168 h with the HIV-1 molecular clone NL4-3 or had been treated as a mock-infection control. Two sets of L1 primers were utilized in this experiment: one pair targeted the 3= end of ORF2 of an alignment of human-specific (L1Hs) and primate-amplified (L1PA) elements, while the second pair targeted ORF1 consensus sequence of highly active "hot" L1 elements (3). It is important to note, however, that, given the vast complement of L1 element sequence in the human genome, we were unable to design primers that would be exclusively limited to these subsets. Thus, the ORF1 primers target many L1 elements in addition to the "hot" elements, and the ORF2 primers also target elements that are not classified as L1Hs or L1PA. In samples from three separate HIV-1-uninfected donors we observed elevated quantities of L1-ORF2 and L1-ORF1 DNA in HIV-1-infected cells compared to mockinfected cells (L1-ORF1, mean ϭ 1.4-fold, P ϭ 0.028; L1-ORF2, mean ϭ 1.5-fold, P ϭ 0.006, Fig. 3A) . The Alu elements are a class of nonautonomous retrotransposable elements that parasitize the L1 retrotransposition machinery to achieve their own replication. We hypothesized that L1 activity in HIV-1-infected cells would result in retrotransposition of Alu elements. We observed a 2.0-fold-higher quantity of Alu DNA in HIV-1-NL4-3-infected cells compared to mock-infected cells (P ϭ 0.001, Fig. 3A) . Similar results were obtained after infecting primary CD4 ϩ T cells with HIV-1 from tonsil-derived lymphoid tissue (Fig. 3B) .
In order to determine the kinetics of L1 and Alu DNA increases in association with HIV-1 infection, we sampled mock-and HIV-1-NL4-3-infected CD4
ϩ T cells at six time points. We observed progressive increases in L1 and Alu relative DNA quantifications by SYBR qPCR, mirroring the kinetics of HIV-1-NL4-3 DNA replication (Fig. 3C to F) . This progressive increase in L1 and Alu quantification was observed in cells from six different HIV-1-uninfected subjects using a variety of experimental protocols. The results from a second experiment, using cells from a different individual, are shown in Fig. 3G . Increased L1 copy numbers were also confirmed using TaqMan qPCR with primers and probes for TBP and for the consensus "hot" sequence of L1-ORF2. Absolute quantities at baseline and at multiple time points postinfection were established by comparison to TBP and L1-ORF2 containing plasmid standards and are given in Table 3 . Representative absolute qPCR data are given in Fig. 3H . To determine whether the L1 copy number increases due to HIV-1 infection were restricted to HIV-1-infected cells or were also associated with a bystander effect of infection, we sorted viable CD4
ϩ T cell cells after 172 h of HIV-1 infection with the R5-tropic strain HIV-1-81A into Gag ϩ and Gag Ϫ subsets by flow cytometry (Fig. 4A) . We observed elevated levels of L1-ORF2 and Alu in DNA from the Gag ϩ subset, but not in the Gag Ϫ subset, compared to the mock infection control (Fig. 4B) . These data support that HIV-1 infection results in the rapid amplification of L1 and Alu DNA, a finding consistent with the induction of L1 reverse transcription.
The majority of accumulated L1 DNA is not contained within HMW gDNA. To test whether novel L1 DNA sequences were integrated into high-molecular weight (HMW) genomic DNA (gDNA), we obtained DNA from 168 h HIV-1-NL4-3 and mock-infected CD4 ϩ T cell samples and isolated HMW gDNA by electrophoresis (Fig. 4C) . Although we did observe significantly higher levels of L1-ORF2 DNA in the gel-purified HMW DNA from HIV-1-infected cells compared to that from the mock-infected control (1.4-fold higher, P ϭ 0.0018, Fig. 4D ), these differences were diminished relative to those observed in the total DNA from these same samples (2.2-fold higher L1-ORF2 relative quantitation in NL4-3 versus mock total DNA samples, Fig. 4E ). These data support that the majority of the additional L1 DNA generated upon HIV-1 infection is not contained within HMW gDNA. We further acknowledge the possibility that low-molecular-weight DNA may not fully dissociate from HMW genomic DNA during electrophoresis; hence, these data cannot be interpreted as definitively indicating that a component of the L1 DNA generated in HIV-1-infected cells is incorporated into HMW gDNA. Thus, while our data clearly indicate that L1 DNA accumulates in HIV-1-infected cells, it cannot be inferred from these qPCR data that retrotransposition is the primary etiology for this copy number increase in primary CD4 ϩ T cells. Effect of HIV-1 infection on L1 RNA levels. The increase in L1 DNA copy number was preceded by a transient increase in L1 RNA in HIV-1-infected cells; however, the latter did not show a progressive increase over time and therefore did not parallel the observed increases in L1 DNA quantities (Fig. 5) . The levels of L1 RNA as measured by the L1-3=UTR and L1-ORF1 primers were elevated in HIV-1-infected primary CD4
ϩ T cells at 24 h postinfection (2.2-fold higher [P ϭ 0.0049] for L1-3=UTR and 2.0-fold higher [P ϭ 0.0011] for L1-ORF1), but neither L1-ORF1 nor L1-3=UTR RNA was significantly different from mock infection controls at 72 h postinfection. At 144 h infection, L1-ORF1 RNA was marginally elevated in HIV-1-infected cells (1.2-fold, P ϭ 0.009), while the slightly higher level of L1-3=UTR observed in HIV-1-infected cells did not reach statistical significance (1.2-fold higher, P ϭ 0.1842). Thus, L1 transcript levels exhibit a transient increase after HIV-1 infection.
Novel L1 genomic insertions are not detected by standard sequencing of L1 flanking regions. In order to determine whether the L1 DNA copy number increases in HIV-1-infected cells were associated with the generation of novel L1 insertion sites in gDNA, we obtained 96 sequences of L1 3= flanking regions from the gDNA of HIV-1-infected primary CD4 ϩ T cells (for which a L1 DNA copy number increase had been demonstrated). Of these 96 sequences, 87 could be mapped to known L1 insertions in the human genome reference sequence. Of the nine remaining sequences: four had been previously identified in 293T cells and hence were likely to represent polymorphic L1 insertions (rather than de novo insertions generated over the course of HIV-1 infection). Two of the remaining sequences were inserted into repetitive DNA and could not be characterized further. For the remaining three sequences, we designed primers corresponding to the genomic DNA sequences flanking the putative novel L1 insertion site and attempted to amplify these sequences from gDNA taken from uninfected cells from the same subject. We were able to amplify and sequence each of these L1 insertions from this uninfected cell DNA, confirming that these represent polymorphic L1 insertions rather than novel insertions generated upon HIV-1 infection (data not shown). Thus, we were unable to identify novel ϩ T cells from three HIV-1-uninfected donors were either infected with a 0.05 MOI of HIV-1-NL4-3 or maintained as mock infection controls. L1-ORF1, L1-ORF2, Alu, Tim-3, and TBP were quantified in DNA from 168 h postinfection using SYBR qPCR. In this experiment, L1-ORF2 was quantified by using the primers "LH1for/LH2rev" (see Table 1 ). The mean TBPstandardized quantitations in infected samples (black bars) are expressed relative to the mock infection controls (white bars) for each donor. Six replicates were performed for each sample, the error bars represent the standard errors, and the P values were calculated by using the Mann-Whitney test. (B) CD4 ϩ T cells from tonsillar lymphoid tissue were either infected with a 0.05 MOI of HIV-1-NL4-3 or maintained as a mock-infection control. The DNA quantitations are shown from 144 h postinfection, standardized to the combined relative mean of four constant copy genes-NFIb, ␤-actin, Tim-3, and TBP-and expressed relative to the mock-infection control. Three replicates were performed for each sample. (C to E) CD4 ϩ T cells from an HIV-1-uninfected donor were either infected with a 0.05 MOI of HIV-1-NL4-3 or maintained as a mock-infected control. Samples were taken at the indicated time points. (C) The kinetics of the HIV-1 infection were monitored at both the protein and the DNA levels (note the secondary y axis). Samples were stained with fluorochrome-conjugated antibodies to CD4 and HIV-1-Gag (intracellularly) and analyzed by flow cytometry. TBP and HIV-1-gag were quantified in DNA from matched samples by SYBR qPCR. The %Gag ϩ values in NL4-3-infected (blue) and mock-infected (orange) samples, as well as the quantities of gag DNA in NL4-3-infected (red) and mock-infected (green) samples, are shown. DNA quantitation was standardized to Tim-3 and expressed relative to a 144 h NL4-3 infection DNA standard. (D to F) Mean DNA quantitations for L1-ORF2 (using the primers LH2for/LH3rev) (D), L1-ORF1 (E), and Alu (F). In each graph, DNA quantifications for NL4-3-infected (solid lines) and mock-infected (dashed lines) samples were standardized to Tim-3 and expressed relative to the baseline 0-h sample. HIV-1-gag DNA quantification is overlaid as a reference (right y axis). Six replicates were performed for every quantitation shown in panels D to F. The P values were calculated by the Mann-Whitney test, comparing mock-infected to HIV-1-infected samples at each time point (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001). (G) CD4 ϩ T cells from a second representative HIV-1-uninfected donor were infected with a 0.02 MOI of R5-tropic HIV-1-81A or maintained as a mock infection control. L1-ORF1, L1-ORF2 (primers LH1for/LH2rev), Alu, Tim-3, ␤-actin, TBP, and NFIb DNA were quantitated at the indicated time points postinfection by SYBR qPCR. The mean standardized DNA quantifications expressed relative to the mock infection DNA quantifications for each donor are shown. Standardization was performed against a combined mean of the relative quantifications of the housekeeping genes: Tim-3, ␤-actin, TBP, and NFIb. Analogous experiments were performed on cells from five different donors with similar results. (H) CD4 ϩ T cells from HIV-1-uninfected donors were either infected with a 0.05 MOI of HIV-1-NL4-3 or maintained as mock infection controls. TBP and L1-ORF2 were quantitated in DNA from the indicated time points using TaqMan qPCR standardized to linearized plasmids. Six replicates were performed for each sample, and error bars represent the standard errors. Summary data for absolute quantitations are given in Table 3 . genomic L1 insertion sites in HIV-1-infected cells using this method.
Failure to identify novel L1 genomic insertions using a subtractive hybridization technique. We next applied a targeted genomic difference analysis (TGDA) technique to enhance our sensitivity to selectively isolate any L1 insertions that may be unique to the gDNA of HIV-1-infected cells (not present in preinfection samples from the same individual). This method has been previously validated for describing distinct L1 insertions between species (69) . Despite sequencing 675 L1 insertion sites from the enriched library, we failed to identify novel L1 insertion sites not represented in published genomic sequences (data not shown). Collectively, these data argue against target-primed reverse transcription of L1 DNA into the genome as a major contributor to the observed L1 DNA copy number increases and thus support the accumulating L1 DNA in HIV-1-infected cells is primarily extrachromosomal in nature. Given the technical difficulty of isolating novel L1 insertions from primary cells, these data do not, however, rule out that, as in Jurkat cells, some level of L1 retrotransposition into gDNA is induced in HIV-1-infected primary CD4 ϩ T cells.
DISCUSSION
To our knowledge, the present study is the first to consider the possibility of interactions between the exogenous retrovirus HIV-1 and the endogenous retrotransposable L1 elements that make up a considerable portion of our genome. In a L1 retrotransposition assay, where only bona fide genomic L1 insertions are detectable, we observed the induction of L1 retrotransposition in Jurkat cells. When we attempted to extend our observations from Jurkat cells into primary CD4 ϩ cells, we made the surprising observation that thousands of additional L1 DNA sequences per cell accumulated in infected cultures over 144 h. Enriching for HMW genomic DNA effectively depleted the majority of this copy number increase, suggesting that retrotransposition into the genome was not the primary mode of generation of additional L1 DNA. Further supporting this, we were unable to identify novel L1 genomic insertions by sequencing L1 flanking DNA. In considering these data, it is important to note that for every HIV-1-infected cell the complement of any novel L1 insertions would be expected to be unique. Since these infected cells die within 24 h, they cannot be cloned to generate a population of cells sharing a common set of novel L1 insertions. This may have hampered our ability to detect novel L1 insertions, since there may have been an amplification bias toward the preexisting insertions common to all cells in the population. Furthermore, the uniqueness of putative novel L1 insertions prevented us from using methods such as Southern blotting to study the accumulation of L1 elements in HIV-1-infected cells. Thus, we are prevented, by technical challenges, from definitively determining whether L1 retrotransposition is induced in HIV-1-infected primary T cells.
In Jurkat cells, the induction of L1 retrotransposition was attributable to the combined activities of vif and vpr, since the deletion of either one of these accessory genes resulted in a diminished ability of virus to induce retrotransposition, and virus lacking both genes showed no induction of L1 activity above uninfected controls. We note an intriguing parallel between this and previous studies which have reported that Vif and Vpr independently cause cell cycle arrest and are responsible for HIV-1-induced cytopathicity (70) . The causal relationship, if any, between our finding that Vif and Vpr expression is associated with the induction of L1 retrotransposition and these previous observations is currently unclear. It may be that cell cycle arrest provides an opportunity for higher levels of retrotransposition to occur. However, we also raise the speculative possibility that the induction of L1 activity by Vif and Vpr may be responsible for triggering the DNA damage response in HIV-1-infected cells. We note that the accumulation of ␥-H2AX foci, the G 2 /M cell cycle arrest, and the apoptosis caused by L1 retrotransposition (71) closely parallel observations of the same phenomena in Vpr-transduced cells (72) . Thus, it may be that the interaction between HIV-1, as an exogenous retrovirus, and the endogenous retroelements in our genome play an unappreciated role in the pathology of HIV-1 infection, particularly in the death of CD4 ϩ T cells. We were initially led to explore the possibility of interactions between HIV-1 and endogenous retrotransposable elements by perceiving a connection between the well established role of APOBEC3 proteins in the suppression of L1 retrotransposition and the degradation of some APOBEC3 family members by HIV-1-Vif. Although our results would appear to validate this hypothesis, we must be careful to point out that we have not yet definitively demonstrated that the induction of L1 retrotransposition by Vif acts through an APOBEC3-dependent mechanism. It also should be noted that some of the APOBEC3 family members shown to be expressed in our Jurkat cells are both known to inhibit L1 retrotransposition and are resistant to degradation by Vif (such as APOBEC3A). Thus, the cumulative inhibition of L1 by APOBEC3 proteins may be diminished but not abrogated by the actions of Vif. It is tempting to speculate, however, that the L1 retrotransposable elements in our genomes may serve a protective role by acting as sensors for the presence of viral countermeasures to host restriction factors. In one proposed scenario, HIV-1-Vif degrades APOBEC3 proteins, permitting the induction of L1 retrotransposition, which then results in the death of the infected cell by causing DNA damage.
In addition to the potential for direct cytopathic effects of HIV-1-induced L1 and Alu activity, we raise the possibility that the accumulation of extrachromosomal L1 and Alu DNA may trigger an innate immune response to infected cells. Innate immune sensing of extrachromosomal DNA plays a critical role in both the early response to many types of infection and in the pathogenesis of some autoimmune diseases (32, (73) (74) (75) (76) (77) . Recently, a wealth of knowledge has been generated regarding the mechanisms of innate immune sensing of DNA, particularly that in the cytoplasm through sensors such as DAI, and AIM2 (78, 79 ; reviewed in reference 80). In the case of HIV-1, it has been suggested that the HIV-1-induced IFN response involves sensing of ssDNA that signals through the STING/TBK1/IRF3 pathway (81) . Although this may be driven by direct sensing of HIV-1 reverse transcription intermediates, our findings also raise the possibility of an indirect mechanism whereby HIV-1 infection induces the accumulation of retroelement DNA which then triggers innate immune responses. Future work will seek to delineate the nature of the extrachromosomal L1 and Alu DNA and study mechanisms by which this may interact with innate immune receptors.
